{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:15:34Z","timestamp":1792588534545,"version":"4.5.0"},"reference-count":201,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Preeclampsia affects 3-4% of pregnancies with adverse effects for both mother and child. Minimal therapeutic options are available, and biomarkers are urgently needed to identify those at greatest risk early in the pregnancy. Both the innate and adaptive immune systems are well regulated during normal pregnancy including the complement system. A functioning complement system with some degree of complement activation participates in proper placental development, ensuring a healthy pregnancy and assisting with host defense. However, aberrant complement activation can lead to adverse pregnancy outcomes such as preeclampsia. An overview of the complement system will be presented, along with review of the pre-clinical literature in animal models providing evidence for complement involvement in maintaining a normal pregnancy and contributing to symptoms of preeclampsia. In addition, clinical studies with evaluation of complement biomarkers in plasma and urine implicate complement dysregulation in the pathophysiology of subtypes of preeclampsia including HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome. Recent studies on the genetics of complement dysregulation in preeclampsia will be reviewed, along with updates on use of recently developed complement therapeutics. The potential utility of evaluating complement activation or manipulating complement during pregnancy will be discussed in view of the successful use of complement therapeutics in pregnancy in other immune diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1643896","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:33:51Z","timestamp":1753335231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The role of complement in normal pregnancy and preeclampsia"],"prefix":"10.3389","volume":"16","author":[{"given":"Richard M.","family":"Burwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Java","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean F.","family":"Regal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01016-y","article-title":"Canonical and non-canonical roles of complement in atherosclerosis","volume":"21","author":"Maffia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1419540","article-title":"Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities","volume":"15","author":"Balduit","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01308","article-title":"Complement nomenclature-deconvoluted","volume":"10","author":"Bohlson","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-230706","article-title":"The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly","volume":"27","author":"Escudero-Esparza","year":"2013","journal-title":"FASEB J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molimm.2018.05.023","article-title":"Novel potential inhibitors of complement system and their roles in complement regulation and beyond","volume":"102","author":"Gialeli","year":"2018","journal-title":"Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.4419","article-title":"CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues","volume":"176","author":"Kraus","year":"2006","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.134.2.1101","article-title":"Species specificity of recognition by the alternative pathway of complement","volume":"134","author":"Horstmann","year":"1985","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220741","article-title":"Species-specific restriction of complement by HRF20 (CD59) generated by cDNA transfection","volume":"22","author":"Takizawa","year":"1992","journal-title":"Eur J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13083","article-title":"Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species","volume":"157","author":"Zelek","year":"2019","journal-title":"Immunology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.07.016","article-title":"Role of complement receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney","volume":"67","author":"Java","year":"2015","journal-title":"Mol Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2736(02)00686-7","article-title":"Critical review of acylation-stimulating protein physiology in humans and rodents","volume":"1609","author":"Cianflone","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8193932","DOI":"10.1155\/2017\/8193932","article-title":"The controversial C5a receptor C5aR2: its role in health and disease","volume":"2017","author":"Zhang","year":"2017","journal-title":"J Immunol Res"},{"key":"B14","article-title":"The leukocyte complement system","volume":"41","author":"Sundsmo","year":"1982","journal-title":"Fed Proc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.018","article-title":"Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation","volume":"39","author":"Liszewski","year":"2013","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-neuro-061010-113810","article-title":"The complement system: an unexpected role in synaptic pruning during development and disease","volume":"35","author":"Stephan","year":"2012","journal-title":"Annu Rev Neurosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-24-01127","article-title":"Synaptic pruning mechanisms and application of emerging imaging techniques in neurological disorders","author":"Xing","year":"2025","journal-title":"Neural Regener Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.immuni.2019.12.004","article-title":"Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease","volume":"52","author":"Werneburg","year":"2020","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13135","article-title":"Intracellular complement: Evidence, definitions, controversies, and solutions","volume":"313","author":"King","year":"2023","journal-title":"Immunol Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2019.1580515","article-title":"Intracellular cytosolic complement component C3 regulates cytoprotective autophagy in pancreatic beta cells by interaction with ATG16L1","volume":"15","author":"King","year":"2019","journal-title":"Autophagy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmet.2018.09.009","article-title":"Complement Component C3 Is Highly Expressed in Human Pancreatic Islets and Prevents beta Cell Death via ATG16L1 Interaction and Autophagy Regulation","volume":"29","author":"King","year":"2019","journal-title":"Cell Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89412","article-title":"A C3(H20) recycling pathway is a component of the intracellular complement system","volume":"127","author":"Elvington","year":"2017","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2009.06.124","article-title":"Complement production by trophoblast cells at the feto-maternal interface","volume":"82","author":"Bulla","year":"2009","journal-title":"J Reprod Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.12.025","article-title":"Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium","volume":"45","author":"Bulla","year":"2008","journal-title":"Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)32330-4","article-title":"Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy","volume":"142","author":"Weinstein","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)90376-i","article-title":"The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing","volume":"162","author":"Sibai","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2010.020","article-title":"The HELLP syndrome","volume":"65","author":"Kirkpatrick","year":"2010","journal-title":"Acta Clin Belg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2420382","DOI":"10.1001\/jamanetworkopen.2024.20382","article-title":"Preeclampsia, fetal growth restriction, and 24-month neurodevelopment in very preterm infants","volume":"7","author":"Check","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41576-019-0169-4","article-title":"Mechanisms of early placental development in mouse and humans","volume":"21","author":"Hemberger","year":"2020","journal-title":"Nat Rev Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/biolre\/ioy049","article-title":"Hemochorial placentation: development, function, and adaptations","volume":"99","author":"Soares","year":"2018","journal-title":"Biol Reprod"},{"key":"B31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/imr.13169","article-title":"Alternative pathway activation in pregnancy, a measured amount \u201ccomplements\u201d a successful pregnancy, too much results in adverse events","volume":"313","author":"Smith-Jackson","year":"2023","journal-title":"Immunol Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17529","article-title":"Identification of complement factor H variants that predispose to pre-eclampsia: A genetic and functional study","volume":"130","author":"Lokki","year":"2023","journal-title":"BJOG"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.05.016","article-title":"Thrombotic microangiopathy in pregnancy: current understanding and management strategies","volume":"9","author":"Urra","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11906-017-0784-4","article-title":"The complement system and preeclampsia","volume":"19","author":"Regal","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2010.01.021","article-title":"Activation of the complement system in normal pregnancy and preeclampsia","volume":"47","author":"Derzsy","year":"2010","journal-title":"Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030308","article-title":"Pulling the trigger in atypical hemolytic uremic syndrome: the role of pregnancy","volume":"21","author":"Goodship","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-pathol-012615-044145","article-title":"Complement dysregulation and disease: insights from contemporary genetics","volume":"12","author":"Liszewski","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.3389\/fimmu.2019.03098","article-title":"Dysregulation of complement activation and placental dysfunction: A potential target to treat preeclampsia","volume":"10","author":"Pierik","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116316","article-title":"Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts","volume":"91","author":"Zhou","year":"1993","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118447","article-title":"Hypoxia alters early gestation human cytotrophoblast differentiation\/invasion in vitro and models the placental defects that occur in preeclampsia","volume":"97","author":"Genbacev","year":"1996","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.9.5949","article-title":"Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles","volume":"178","author":"Germain","year":"2007","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(89)90665-0","article-title":"Preeclampsia: an endothelial cell disorder","volume":"161","author":"Roberts","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1705","article-title":"Specificity of vascular endothelial cell growth factor receptor ligand binding domains","volume":"201","author":"Kendall","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e13033","DOI":"10.1111\/aji.13033","article-title":"Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells","volume":"80","author":"Banadakoppa","year":"2018","journal-title":"Am J Reprod Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/10641955.2019.1640725","article-title":"Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia","volume":"38","author":"Yonekura Collier","year":"2019","journal-title":"Hypertens Pregnancy"},{"key":"B49","doi-asserted-by":"publisher","first-page":"103322","DOI":"10.1016\/j.jri.2021.103322","article-title":"Complement activation by an angiogenic imbalance leads to systemic vascular endothelial dysfunction: A new proposal for the pathophysiology of preeclampsia","volume":"145","author":"Matsuyama","year":"2021","journal-title":"J Reprod Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.04.009","article-title":"Complement activation is critical for placental ischemia-induced hypertension in the rat","volume":"56","author":"Lillegard","year":"2013","journal-title":"Mol Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402220","article-title":"Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency","volume":"195","author":"Gelber","year":"2015","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701008R","article-title":"Angiogenic factor imbalance precedes complement deposition in placentae of the BPH\/5 model of preeclampsia","volume":"32","author":"Sones","year":"2018","journal-title":"FASEB J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061022","article-title":"Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction","volume":"203","author":"Girardi","year":"2006","journal-title":"J Exp Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jri.2016.09.001","article-title":"Alternative functions of the complement protein C1q at embryo implantation site","volume":"119","author":"Agostinis","year":"2017","journal-title":"J Reprod Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)80298-2","article-title":"Phenotypes of complement knockouts","volume":"49","author":"Holers","year":"2000","journal-title":"Immunopharmacology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.175919","article-title":"Role of complement component C1q in the onset of preeclampsia in mice","volume":"58","author":"Singh","year":"2011","journal-title":"Hypertension"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903215","article-title":"An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development","volume":"185","author":"Agostinis","year":"2010","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120147","article-title":"Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice","volume":"3","author":"Garrett","year":"2018","journal-title":"JCI Insight"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00353.2019","article-title":"Paternal deficiency of complement component C1q leads to a preeclampsia-like pregnancy in wild-type female mice and vascular adaptations postpartum","volume":"318","author":"Sutton","year":"2020","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00312","article-title":"Complement activation and regulation in preeclamptic placenta","volume":"5","author":"Lokki","year":"2014","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.882298","article-title":"Distinct roles of classical and lectin pathways of complement in preeclamptic placentae","volume":"13","author":"Belmonte","year":"2022","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2009.08.004","article-title":"Early regulators in abortion and implications for a preeclampsia model","volume":"82","author":"Chaouat","year":"2009","journal-title":"J Reprod Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501361","article-title":"Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating","volume":"195","author":"Petitbarat","year":"2015","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e13663","DOI":"10.1371\/journal.pone.0013663","article-title":"A new mouse model to explore therapies for preeclampsia","volume":"5","author":"Ahmed","year":"2010","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1387\/ijdb.092993mu","article-title":"Complement component C3 functions as an embryotrophic factor in early postimplantation rat embryos","volume":"54","author":"Usami","year":"2010","journal-title":"Int J Dev Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/mrd.20955","article-title":"Regulation of complement-3 protein expression in human and mouse oviducts","volume":"76","author":"Lee","year":"2009","journal-title":"Mol Reprod Dev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1277","article-title":"Preimplantation embryos cooperate with oviductal cells to produce embryotrophic inactivated complement-3b","volume":"149","author":"Tse","year":"2008","journal-title":"Endocrinology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311160200","article-title":"The embryotrophic activity of oviductal cell-derived complement C3b and iC3b, a novel function of complement protein in reproduction","volume":"279","author":"Lee","year":"2004","journal-title":"J Biol Chem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/mrd.21013","article-title":"Complement 3 deficiency impairs early pregnancy in mice","volume":"76","author":"Chow","year":"2009","journal-title":"Mol Reprod Dev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/biology9090304","article-title":"Complement in reproductive white adipose tissue characterizes the obese preeclamptic-like BPH\/5 mouse prior to and during pregnancy","volume":"9","author":"Olson","year":"2020","journal-title":"Biol (Basel)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2011.10.012","article-title":"Complement fragment C3a controls mutual cell attraction during collective cell migration","volume":"21","author":"Carmona-Fontaine","year":"2011","journal-title":"Dev Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/dvg.23008","article-title":"Xenopus as a model organism to study heterotrimeric G-protein pathway during collective cell migration of neural crest","volume":"55","author":"Toro-Tapia","year":"2017","journal-title":"Genesis"},{"key":"B73","article-title":"Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid","volume":"73","author":"Haeger","year":"1989","journal-title":"Obstet Gynecol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/AOG.0b013e3181fc3afa","article-title":"Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes","volume":"117","author":"Lynch","year":"2011","journal-title":"Obstet Gynecol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.02.035","article-title":"Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia","volume":"206","author":"Lynch","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.molimm.2020.03.021","article-title":"Dysregulation of complement system during pregnancy in patients with preeclampsia: A prospective study","volume":"122","author":"He","year":"2020","journal-title":"Mol Immunol"},{"key":"B77","first-page":"698","article-title":"Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count","volume":"76","author":"Haeger","year":"1990","journal-title":"Obstet Gynecol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12541","article-title":"Expression of the complement system\u2019s activation factors in plasma of patients with early\/late-onset severe pre-eclampsia","volume":"76","author":"He","year":"2016","journal-title":"Am J Reprod Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3109\/14767050903301009","article-title":"Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products","volume":"23","author":"Soto","year":"2010","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","article-title":"Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy","volume":"62","author":"Burwick","year":"2013","journal-title":"Hypertension"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12586","article-title":"Complement component C1q as potential diagnostic but not predictive marker of preeclampsia","volume":"76","author":"Agostinis","year":"2016","journal-title":"Am J Reprod Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.06.024","article-title":"Assessment of blood-brain barrier integrity and neuroinflammation in preeclampsia","volume":"221","author":"Burwick","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03456","article-title":"Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia","volume":"64","author":"Burwick","year":"2014","journal-title":"Hypertension"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111072","article-title":"C3a and C5a promote renal ischemia-reperfusion injury","volume":"23","author":"Peng","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8621","article-title":"Predominant role for C5b-9 in renal ischemia\/reperfusion injury","volume":"105","author":"Zhou","year":"2000","journal-title":"J Clin Invest"},{"key":"B86","doi-asserted-by":"publisher","first-page":"263109","DOI":"10.1155\/2015\/263109","article-title":"Complement split products in amniotic fluid in pregnancies subsequently developing early-onset preeclampsia","author":"Banadakoppa","year":"2015","journal-title":"Dis Markers"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.218123","article-title":"Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats","volume":"351","author":"Lillegard","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI4106","article-title":"Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor","volume":"103","author":"Wallukat","year":"1999","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.25.641","article-title":"Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension","volume":"25","author":"Liao","year":"2002","journal-title":"Hypertens Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e2127587","DOI":"10.1001\/jamanetworkopen.2021.27587","article-title":"Association of angiotensin II type 1 receptor agonistic autoantibodies with outcomes in patients with acute aortic dissection","volume":"4","author":"Wu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000154785.50570.63","article-title":"Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia","volume":"45","author":"Dechend","year":"2005","journal-title":"Hypertension"},{"key":"B93","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1161\/CIRCRESAHA.113.300752","article-title":"Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond","volume":"113","author":"Xia","year":"2013","journal-title":"Circ Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1856","article-title":"Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice","volume":"14","author":"Zhou","year":"2008","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.191817","article-title":"Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia","volume":"60","author":"Wang","year":"2012","journal-title":"Hypertension"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.591398","article-title":"The \u201cC3aR antagonist\u201d SB290157 is a partial C5aR2 agonist","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15264","article-title":"Is the C3a receptor antagonist SB290157 a useful pharmacological tool","volume":"177","author":"Lee","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.137935","article-title":"Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1","volume":"54","author":"LaMarca","year":"2009","journal-title":"Hypertension"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10681","article-title":"AT1-AA (Angiotensin II type 1 receptor agonistic autoantibody) blockade prevents preeclamptic symptoms in placental ischemic rats","volume":"71","author":"Cunningham","year":"2018","journal-title":"Hypertension"},{"key":"B100","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.molimm.2016.08.016","article-title":"Role of IgM and angiotensin II Type I receptor autoantibodies in local complement activation in placental ischemia-induced hypertension in the rat","volume":"78","author":"Regal","year":"2016","journal-title":"Mol Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e2424754122","DOI":"10.1073\/pnas.2424754122","article-title":"Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury","volume":"122","author":"Bongoni","year":"2025","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2012.07.024","article-title":"The complement system in ischemia-reperfusion injuries","volume":"217","author":"Gorsuch","year":"2012","journal-title":"Immunobiology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e18291","DOI":"10.1111\/jcmm.18291","article-title":"A single-chain antibody construct with specificity of a natural IgM antibody reduces hepatic ischemia reperfusion injury in mice","volume":"28","author":"Yang","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.07.004","article-title":"Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope","volume":"40","author":"Zheng","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.194324","article-title":"Preeclampsia is characterized by placental complement dysregulation","volume":"60","author":"Buurma","year":"2012","journal-title":"Hypertension"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05484","article-title":"Classical complement pathway activation in the kidneys of women with preeclampsia","volume":"66","author":"Penning","year":"2015","journal-title":"Hypertension"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842451","article-title":"Circulating levels of anti-C1q and anti-factor H autoantibodies and their targets in normal pregnancy and preeclampsia","volume":"13","author":"Dijkstra","year":"2022","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1037191","article-title":"A longitudinal study of C1q and anti-C1q autoantibodies in homologous and heterologous pregnancies for predicting pre-eclampsia","volume":"13","author":"Agostinis","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.24552","article-title":"Preeclamptic placental CD19+ B cells are causal to hypertension during pregnancy","volume":"82","author":"Herrock","year":"2025","journal-title":"Hypertension"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.167569","article-title":"Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes","volume":"57","author":"LaMarca","year":"2011","journal-title":"Hypertension"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00132.2019","article-title":"Role of B1 and B2 lymphocytes in placental ischemia-induced hypertension","volume":"317","author":"Laule","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00033.2020","article-title":"Letter to the Editor: Importance of B cells in response to placental ischemia","volume":"318","author":"LaMarca","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00104.2020","article-title":"Reply to \u201cLetter to the Editor: Importance of B cells in response to placental ischemia\u201d","volume":"318","author":"Regal","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1769","article-title":"Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor","volume":"107","author":"Perosa","year":"2006","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00190.2022","article-title":"B2 cells contribute to hypertension and natural killer cell activation possibly via AT1-AA in response to placental ischemia","volume":"324","author":"Herrock","year":"2023","journal-title":"Am J Physiol Renal Physiol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e13693","DOI":"10.1111\/aji.13693","article-title":"Inhibiting B cell activating factor attenuates preeclamptic symptoms in placental ischemic rats","volume":"89","author":"Herrock","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002980","article-title":"Terminal complement activation in preeclampsia","volume":"132","author":"Burwick","year":"2018","journal-title":"Obstet Gynecol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.3.1818","article-title":"Molecular weight of the membrane C5b-9 complex of human complement: characterization of the terminal complex as a C5b-9 monomer","volume":"78","author":"Bhakdi","year":"1981","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.143.2.546","article-title":"Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy","volume":"143","author":"Kerjaschki","year":"1989","journal-title":"J Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V114700","article-title":"Complement activation products in the urine from proteinuric patients","volume":"11","author":"Morita","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12349","article-title":"Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia","volume":"73","author":"Guseh","year":"2015","journal-title":"Am J Reprod Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2008.07.008","article-title":"The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro","volume":"29","author":"Rampersad","year":"2008","journal-title":"Placenta"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.261428398","article-title":"Complement activation in factor D-deficient mice","volume":"98","author":"Xu","year":"2001","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B124","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","article-title":"Adipsin is an adipokine that improves beta cell function in diabetes","volume":"158","author":"Lo","year":"2014","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"20073","DOI":"10.1038\/srep20073","article-title":"Serum adipsin levels throughout normal pregnancy and preeclampsia","volume":"6","author":"Poveda","year":"2016","journal-title":"Sci Rep"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702385","article-title":"Adipsin of the alternative complement pathway is a potential predictor for preeclampsia in early pregnancy","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.10.025","article-title":"Animal models of preeclampsia: investigating pathophysiology and therapeutic targets","volume":"226","author":"Bakrania","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2005.00318.x","article-title":"Low erythrocyte complement receptor type 1 (CR1, CD35) expression in preeclamptic gestations","volume":"54","author":"Feinberg","year":"2005","journal-title":"Am J Reprod Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1126\/science.287.5452.498","article-title":"A critical role for murine complement regulator crry in fetomaternal tolerance","volume":"287","author":"Xu","year":"2000","journal-title":"Science"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00321-2","article-title":"Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway","volume":"19","author":"Mao","year":"2003","journal-title":"Immunity"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.09.003","article-title":"Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury","volume":"46","author":"Ruseva","year":"2009","journal-title":"Mol Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e0236968","DOI":"10.1371\/journal.pone.0236968","article-title":"Complement inhibitor Crry expression in mouse placenta is essential for maintaining normal blood pressure and fetal growth","volume":"15","author":"Banadakoppa","year":"2020","journal-title":"PloS One"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.2.628","article-title":"Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting","volume":"96","author":"Sun","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4049\/jimmunol.1900527","article-title":"Complement in motion: the evolution of CD46 from a complement regulator to an orchestrator of normal cell physiology","volume":"203","author":"Liszewski","year":"2019","journal-title":"J Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2013.09.016","article-title":"CD46: the \u2018multitasker\u2019 of complement proteins","volume":"45","author":"Yamamoto","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.442","article-title":"Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria","volume":"98","author":"Holt","year":"2001","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2020.10.004","article-title":"Plasma CD59 concentrations are increased in preeclampsia with severe features and correlate with laboratory measures of end-organ injury","volume":"22","author":"Velasquez","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"B138","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1038\/s41467-019-12522-w","article-title":"Rare mutations in the complement regulatory gene CSMD1 are associated with male and female infertility","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"key":"B139","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12888-019-2089-4","article-title":"Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Psychiatry"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-072211-110606","article-title":"Defective complement inhibitory function predisposes to renal disease","volume":"64","author":"Java","year":"2013","journal-title":"Annu Rev Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000543","article-title":"Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy","volume":"2024","author":"Java","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144691","article-title":"Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"112","author":"Fakhouri","year":"2008","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort","volume":"8","author":"Salmon","year":"2011","journal-title":"PloS Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2012.694923","article-title":"The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome","volume":"25","author":"Crovetto","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99128","article-title":"Germline mutations in the alternative pathway of complement predispose to HELLP syndrome","volume":"3","author":"Vaught","year":"2018","journal-title":"JCI Insight"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-024-00310-6","article-title":"Understanding rare genetic variants within the terminal pathway of complement system in preeclampsia","volume":"26","author":"Lokki","year":"2025","journal-title":"Genes Immun"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16660","article-title":"Dysfunction of complement receptors CR3 (CD11b\/18) and CR4 (CD11c\/18) in pre-eclampsia: a genetic and functional study","volume":"128","author":"Lokki","year":"2021","journal-title":"BJOG"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.01.026","article-title":"Thrombotic microangiopathy after kidney transplantation: insights into genetic etiology and clinical outcomes","volume":"10","author":"Merzkani","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"B153","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.ogx.0000234794.27485.59","article-title":"Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review","volume":"61","author":"Fieni","year":"2006","journal-title":"Obstet Gynecol Surv"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.10.025","article-title":"Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab","volume":"34","author":"Danilov","year":"2010","journal-title":"Leuk Res"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e00294","DOI":"10.1016\/j.crwh.2021.e00294","article-title":"Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report","volume":"30","author":"Fassett","year":"2021","journal-title":"Case Rep Womens Health"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-228709","article-title":"Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia\/HELLP syndrome","volume":"12","author":"Elabd","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.09.045","article-title":"Eculizumab in early-stage pregnancy","volume":"5","author":"Morales","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.06.005","article-title":"Complement C5 inhibition as a novel therapeutic approach in severe pre-eclampsia","volume":"97","author":"Kattah","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1946-x","article-title":"Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review","volume":"103","author":"Miyasaka","year":"2016","journal-title":"Int J Hematol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08099.x","article-title":"The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab","volume":"149","author":"Kelly","year":"2010","journal-title":"Br J Haematol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000248","article-title":"Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab","volume":"26","author":"Vekemans","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N Engl J Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B164","doi-asserted-by":"publisher","first-page":"525.e1","DOI":"10.1016\/j.ajog.2017.01.026","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae178","article-title":"Can complement activation be the missing link in antiphospholipid syndrome","volume":"63","author":"Venturelli","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B166","doi-asserted-by":"publisher","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the \u201cCAPS Registry","volume":"21","author":"Lopez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e6338","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030407","article-title":"The extended use of eculizumab in pregnancy and complement activation(-)Associated diseases affecting maternal, fetal and neonatal kidneys-the future is now","volume":"8","author":"Stefanovic","year":"2019","journal-title":"J Clin Med"},{"key":"B169","doi-asserted-by":"publisher","first-page":"e12584","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report","volume":"97","author":"Rovere-Querini","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-01025-x","article-title":"Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis","volume":"34","author":"Fakhouri","year":"2021","journal-title":"J Nephrol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003570","article-title":"Pregnancy prolongation after eculizumab use in early-onset preeclampsia","volume":"134","author":"Lu","year":"2019","journal-title":"Obstet Gynecol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00548","article-title":"Eculizumab treatment for postpartum HELLP syndrome and aHUS-case report","volume":"11","author":"Lokki","year":"2020","journal-title":"Front Immunol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PloS One"},{"key":"B177","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12882-020-02190-0","article-title":"Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis","volume":"22","author":"G\u00e4ckler","year":"2021","journal-title":"BMC Nephrol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1182\/blood-2024-209857","article-title":"Ravulizumab in pregnant women with paroxysmal nocturnal hemoglobinuria (PNH) - favourable experience from a retrospective case series","volume":"144","author":"Hoechsmann B","year":"2024","journal-title":"Blood"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000687","article-title":"Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy","volume":"28","author":"Schoettler","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-589366","article-title":"Eculizumab fails to inhibit generation of C5a in vivo","volume":"124","author":"Burwick","year":"2014","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-642553","article-title":"Response: Maternal and cord C5a in response to eculizumab","volume":"126","author":"Burwick","year":"2015","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2014.11.003","article-title":"Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn","volume":"220","author":"Hallstensen","year":"2015","journal-title":"Immunobiology"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014746","article-title":"Complement C5 Inhibition in early onset HELLP Syndrome","volume":"9","author":"Gerber","year":"2025","journal-title":"Blood Adv"},{"key":"B186","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.preghy.2018.02.007","article-title":"Thrombotic microangiopathies of pregnancy: Differential diagnosis","volume":"12","author":"Gupta","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.03.019","article-title":"Diagnostic value of biological parameters in biopsy-confirmed thrombotic microangiopathy\u2013MATRIX consortium group","volume":"10","author":"Halimi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70162-X","article-title":"Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome","volume":"175","author":"Audibert","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.preghy.2025.101212","article-title":"Pregnancy-related Thrombotic Microangiopathy has a spectrum of underlying causes","volume":"40","author":"Livson","year":"2025","journal-title":"Pregnancy Hypertens"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17311","article-title":"Differentiating hemolysis, elevated liver enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period","volume":"78","author":"Burwick","year":"2021","journal-title":"Hypertension"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome","volume":"44","author":"Vaught","year":"2016","journal-title":"Exp Hematol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1038\/s41598-021-82733-z","article-title":"Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics","volume":"11","author":"Youssef","year":"2021","journal-title":"Sci Rep"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14040387","article-title":"Increased complement activation and decreased ADAMTS13 activity are associated with genetic susceptibility in patients with preeclampsia\/HELLP syndrome compared to healthy pregnancies: an observational case-controlled study","volume":"14","author":"Venou","year":"2024","journal-title":"J Pers Med"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025850","article-title":"Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy","volume":"144","author":"Cole","year":"2024","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.01.009","article-title":"Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis","volume":"212","author":"van Oostwaard","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/AOG.0000000000003554","article-title":"Pregnancy-associated atypical hemolytic uremic syndrome: A systematic review","volume":"135","author":"Gupta","year":"2020","journal-title":"Obstet Gynecol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16711","article-title":"Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies","volume":"191","author":"Peffault de Latour","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1643896\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:33:52Z","timestamp":1753335232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1643896\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":201,"alternative-id":["10.3389\/fimmu.2025.1643896"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1643896","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1643896"}}